| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5880283 | ABBVIE | 8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same |
Dec, 2015
(8 years ago) | |
|
US5880283 (Pediatric) | ABBVIE | 8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same |
Jun, 2016
(7 years ago) | |
| US6333045 | ABBVIE | Aqueous liquid pharmaceutical composition comprised of gatifloxacin |
Aug, 2019
(4 years ago) | |
|
US6333045 (Pediatric) | ABBVIE | Aqueous liquid pharmaceutical composition comprised of gatifloxacin |
Feb, 2020
(4 years ago) | |
Zymaxid is owned by Abbvie.
Zymaxid contains Gatifloxacin.
Zymaxid has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Zymaxid are:
- US5880283
- US5880283*PED
- US6333045
- US6333045*PED
Zymaxid was authorised for market use on 18 May, 2010.
Zymaxid is available in solution/drops;ophthalmic dosage forms.
The generics of Zymaxid are possible to be released after 20 February, 2020.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 18, 2013 |
Drugs and Companies using GATIFLOXACIN ingredient
Market Authorisation Date: 18 May, 2010
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
How can I launch a generic of ZYMAXID before it's drug patent expiration?
More Information on Dosage
ZYMAXID family patents
